Financial Data and Key Metrics Changes - For the three months ended December 31, 2025, the net loss was $5.3 million or 26 cents per diluted common share, compared to a net loss of $8.9 million or 61 cents per diluted common share in the prior year's quarter [19] - Research and development costs decreased to $1.3 million from $5.7 million in the same period last year, primarily due to the completion of the Phase 2b QUALITY clinical study [17] - General administrative expenses were $4.1 million compared to $5.2 million in the prior quarter, mainly due to a decrease in share-based compensation [17] - Cash, cash equivalents, and restricted cash balance was $33 million as of December 31, 2025, compared to $15.8 million as of September 30, 2025 [19] Business Line Data and Key Metrics Changes - The company is focused on two main drug development programs: enobosarm and sabizabulin, targeting obesity and cardiovascular diseases respectively [3][4] - Enobosarm has shown potential in a Phase 2b clinical trial for obesity, demonstrating selective fat loss while preserving lean mass [6][7] Market Data and Key Metrics Changes - The FDA has provided regulatory clarity for enobosarm in combination with GLP-1 receptor agonists, indicating at least two possible pathways for approval based on weight loss metrics [8][9] Company Strategy and Development Direction - The company aims to develop enobosarm as a next-generation obesity treatment that preserves lean mass and physical function, addressing the limitations of current GLP-1 receptor agonists [4][5] - A planned Phase 2b PLATEAU clinical study will evaluate enobosarm's effects on weight loss and physical function in older patients initiating semaglutide treatment [12][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's cash position to fund operations through the interim analysis of the Phase 2b PLATEAU study [20] - The company is not currently profitable and has experienced negative cash flow from operations, but the recent public offering has bolstered its financial position [19][22] Other Important Information - The company completed a public offering of 1.4 million shares, generating approximately $23.4 million in net proceeds [16] - The company recorded a gain on the sale of the FC2 Female Condom business in the prior year, which is now classified under discontinued operations [17][18] Q&A Session Summary Question: Why not use the oral semaglutide in this study? - Management explained that the injectable form of semaglutide is preferred to minimize differences in outcomes compared to previous studies [24] Question: Did you discuss the stair climb test with the FDA? - Management confirmed discussions with the FDA regarding the stair climb test as a sensitive measure for assessing physical function in the study [26] Question: Are there any pre-specified decision rules for the interim analysis? - It was clarified that there are no futility analysis or sample size re-estimation associated with the interim analysis [32] Question: What degree of weight loss needs to be seen for functional benefit assessment? - Management indicated that greater than 5% weight loss is a clear criterion, but less than 5% could still be acceptable if accompanied by significant functional benefits [34]